

## C-Path's International Neonatal Consortium and the National Association of Neonatal Nurses Open Access to Neonatal Drug Development Education Modules



**NANN**  
**DIGITAL**  
**PRODUCTS**

**Bridging the Gap: Empowering Neonatal Nurses in Drug Development for Neonates**

Access the modules for **FREE**:  
<https://pxl.to/BridgingtheGap>



*The modules will help educate neonatal healthcare professionals in neonatal drug development, pipeline decision-making and addressing neonate needs in the current environment.*

**TUCSON, Ariz., May 7, 2024** — Critical Path Institute (C-Path) today announced the launch of its continuing education (CE) neonatal drug development modules — a collaboration between its International Neonatal Consortium (INC) and the National Association of Neonatal Nurses (NANN).

The decision to develop these modules stems from an INC multi-stakeholder survey aimed at exploring communication practices and stakeholders' perceptions and knowledge regarding the conduct of clinical trials in the neonatal intensive care unit (NICU). The work was led by INC Communication Workgroup co-chair member Mary Short, MSN.

“With a background in both the NICU and the pharmaceutical industry, I bring a nuanced understanding of the critical need to elevate awareness surrounding neonatal drug development,” said Short. “Through collaboration in research education, I am committed to fostering optimal engagement among nurses in neonatal clinical research, recognizing the pivotal role they play in advancing care for our most vulnerable patients.”

“As an organization committed to advancing neonatal research and care, we recognize the vital role that nurses and clinicians play in the hospital setting,” said INC Executive Director Kanwaljit Singh, M.D., MPH. “This collaboration with NANN represents a pivotal step forward in our mission to support and empower neonatal nurses and clinicians. By engaging them in the development of these educational modules, we aim

to enhance their understanding and involvement in neonatal clinical trials and drug development.”

“Consistent with our mission to elevate and transform neonatal care, NANN is grateful to bring forth this important collaboration with INC and give all neonatal nurses access to these outcome-improving modules,” said NANN Executive Director, Molly Anderson. “We know neonatal nurses have the expertise and knowledge to play an essential role in drug development that benefits their patients. NANN seeks out partnerships with organizations like INC that allow us to empower deepened nurse involvement with all aspects of care throughout their careers.”

Recent studies, including findings in, “[The culture of research communication in neonatal intensive care units: key stakeholder perspectives](#),” have underscored the need for enhanced education for nurses in neonatal research. In response, INC has created seven tailored content modules focused on neonatal study design for drug development. These modules, sourced from previous INC neonatal drug development education presentations, have been updated and recorded by members of INC, including nurses.

The goal of the modules is to provide foundational knowledge on innovative, regulated medicines development for neonates, including pipeline decision-making factors and addressing neonatal needs within the current environment.

“NANN’s steadfast support and partnership have been instrumental in driving this initiative forward, and we are grateful for their ongoing commitment to improving outcomes for premature and sick neonates,” Singh added.

INC and NANN are providing the modules free of charge to nurses and other interested stakeholders; nurses completing the models will receive CE/contact hours. For further information on the collaboration and to access the educational modules, [click here](#).

### **About Critical Path Institute**

Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the [FDA’s Critical Path Initiative](#). **C-Path’s mission is to lead collaborations that advance better treatments for people worldwide.** Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit [c-path.org](#).

*Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 54% funded by the FDA/HHS, totaling \$19,436,549, and 46% funded by non-government source(s), totaling \$16,373,368. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.*

### **About National Association of Neonatal Nurses**

As the professional voice and home of neonatal nurses for 40 years, the National Association of Neonatal Nurses supports the advancement of the neonatal nursing profession by providing opportunities to influence care for neonates and their families, collaborate with leaders and peers in their field, and gain clinical knowledge to improve daily practice. Learn more at? [www.nann.org](#)

#### **Contacts:**

Roxan Triolo Olivas  
C-Path

520.954.1634  
[rolivas@c-path.org](mailto:rolivas@c-path.org)

Kissy Black  
C-Path  
615.310.1894  
[kblack@c-path.org](mailto:kblack@c-path.org)